Merz Therapeutics Launches FAMPYRA^® in Canada, EMEA, LATAM and APAC

As part of its strategic vision to become a leader in the specialty neurology space, Merz Therapeutics has launched FAMPYRA^® (fampridine) extended-release tablets (10 mg) in Canada, EMEA, LATAM, and APAC by transitioning the licensing rights to commercialize the product from Biogen. Effective January 2, 2025, Merz Therapeutics assumed full management, distribution, and marketing responsibilities for FAMPYRA^® in 45 countries. These territories include Canada, Austria, Bahrain, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Iceland, Ireland, Israel, Italy, Jordan, Kuwait, Latvia, Lithuania, Luxembourg, Malta, Morocco, Netherlands, Norway, Poland, Portugal, Qatar, Romania, Saudi Arabia, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, Australia, New Zealand, Argentina, Chile, Colombia, and Mexico. 

FAMPYRA^® is an extended-release tablet indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis experiencing walking disabilities. This launch aligns with Merz Therapeutics’ mission to enhance patient outcomes and address unmet needs in the neurology field. 

The acquisition of FAMPYRA^® was completed on July 10, 2024, as part of the acquisition of two FDA-approved products, INBRIJA^® (levodopa inhalation powder) and (F)AMPYRA^® (dalfampridine), and related assets from Acorda Therapeutics. Adding these products to Merz Therapeutics’ portfolio reinforces its longstanding commitment to specialty neurology and to the movement disorder community. 

Learn more about our asset purchase agreement with Acorda Therapeutics here.